Candonilimab
- Generic Name
- Candonilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2394841-59-7
- Unique Ingredient Identifier
- 6FYG1DS4NW
- Background
Cadonilimab is under investigation in clinical trial NCT04220307 (A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma).
- Indication
用于既往接受含铂化疗治疗失败的复发或转移性宫颈癌患者的治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Treatment of Recurrent Glioblastoma With Fractionated Radiotherapy Combined With Cadonilimab
- Conditions
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2023-02-21
- Target Recruit Count
- 11
- Registration Number
- NCT05737368
SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC
- Conditions
- Interventions
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 25
- Registration Number
- NCT05732662
AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2022-10-26
- Target Recruit Count
- 47
- Registration Number
- NCT05594914
Cadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 418
- Registration Number
- NCT05587374
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China
AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)
- Conditions
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 54
- Registration Number
- NCT05578430
Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2022-12-30
- Lead Sponsor
- Akeso
- Target Recruit Count
- 102
- Registration Number
- NCT05559541
- Locations
- 🇨🇳
Tianjin Medical University Cancer Insitute & Hospital, Tianjin, Tianjin, China
AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC
- Conditions
- Interventions
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 80
- Registration Number
- NCT05522894
Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 28
- Registration Number
- NCT05426005
- Locations
- 🇨🇳
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 43
- Registration Number
- NCT05377658
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Akeso
- Target Recruit Count
- 70
- Registration Number
- NCT05256472
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.